vs
EVOLUTION PETROLEUM CORP（EPM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是EVOLUTION PETROLEUM CORP的1.5倍（$30.3M vs $20.7M），EVOLUTION PETROLEUM CORP净利率更高（5.2% vs -221.3%，领先226.5%），REGENXBIO Inc.同比增速更快（43.0% vs 2.0%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -5.2%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EPM vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.7M
营收增速更快
RGNX
高出41.0%
2.0%
净利率更高
EPM
高出226.5%
-221.3%
两年增速更快
RGNX
近两年复合增速
-5.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $30.3M |
| 净利润 | $1.1M | $-67.1M |
| 毛利率 | 44.3% | — |
| 营业利润率 | 3.2% | -190.0% |
| 净利率 | 5.2% | -221.3% |
| 营收同比 | 2.0% | 43.0% |
| 净利润同比 | 158.4% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPMRGNX
| Q4 25 | $20.7M | $30.3M | ||
| Q3 25 | $21.3M | $29.7M | ||
| Q2 25 | $21.1M | $21.4M | ||
| Q1 25 | $22.6M | $89.0M | ||
| Q4 24 | $20.3M | $21.2M | ||
| Q3 24 | $21.9M | $24.2M | ||
| Q2 24 | $21.2M | $22.3M | ||
| Q1 24 | $23.0M | $15.6M |
净利润EPMRGNX
| Q4 25 | $1.1M | $-67.1M | ||
| Q3 25 | $824.0K | $-61.9M | ||
| Q2 25 | $3.4M | $-70.9M | ||
| Q1 25 | $-2.2M | $6.1M | ||
| Q4 24 | $-1.8M | $-51.2M | ||
| Q3 24 | $2.1M | $-59.6M | ||
| Q2 24 | $1.2M | $-53.0M | ||
| Q1 24 | $289.0K | $-63.3M |
毛利率EPMRGNX
| Q4 25 | 44.3% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 46.1% | — | ||
| Q1 25 | 40.7% | — | ||
| Q4 24 | 36.9% | 70.2% | ||
| Q3 24 | 46.2% | 48.8% | ||
| Q2 24 | 46.3% | 52.5% | ||
| Q1 24 | 45.2% | 72.6% |
营业利润率EPMRGNX
| Q4 25 | 3.2% | -190.0% | ||
| Q3 25 | -0.4% | -176.3% | ||
| Q2 25 | 6.3% | -296.3% | ||
| Q1 25 | 7.0% | 13.6% | ||
| Q4 24 | -3.0% | -242.1% | ||
| Q3 24 | 8.5% | -256.6% | ||
| Q2 24 | 11.3% | -251.3% | ||
| Q1 24 | 9.1% | -408.8% |
净利率EPMRGNX
| Q4 25 | 5.2% | -221.3% | ||
| Q3 25 | 3.9% | -208.3% | ||
| Q2 25 | 16.2% | -331.8% | ||
| Q1 25 | -9.7% | 6.8% | ||
| Q4 24 | -9.0% | -241.3% | ||
| Q3 24 | 9.4% | -246.3% | ||
| Q2 24 | 5.8% | -237.7% | ||
| Q1 24 | 1.3% | -405.4% |
每股收益（稀释后）EPMRGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $0.02 | $-1.20 | ||
| Q2 25 | $0.10 | $-1.38 | ||
| Q1 25 | $-0.07 | $0.12 | ||
| Q4 24 | $-0.06 | $-0.99 | ||
| Q3 24 | $0.06 | $-1.17 | ||
| Q2 24 | $0.04 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $67.5M | $102.7M |
| 总资产 | $169.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EPMRGNX
| Q4 25 | $3.8M | $230.1M | ||
| Q3 25 | $714.0K | $274.2M | ||
| Q2 25 | $2.5M | $323.3M | ||
| Q1 25 | $5.6M | $267.9M | ||
| Q4 24 | $11.7M | $234.7M | ||
| Q3 24 | $6.9M | $255.5M | ||
| Q2 24 | $6.4M | $290.4M | ||
| Q1 24 | $3.1M | $338.7M |
股东权益EPMRGNX
| Q4 25 | $67.5M | $102.7M | ||
| Q3 25 | $69.1M | $161.5M | ||
| Q2 25 | $71.8M | $213.7M | ||
| Q1 25 | $71.7M | $274.2M | ||
| Q4 24 | $76.3M | $259.7M | ||
| Q3 24 | $79.6M | $301.4M | ||
| Q2 24 | $81.1M | $348.3M | ||
| Q1 24 | $83.5M | $390.7M |
总资产EPMRGNX
| Q4 25 | $169.3M | $453.0M | ||
| Q3 25 | $169.1M | $525.2M | ||
| Q2 25 | $160.3M | $581.0M | ||
| Q1 25 | $156.4M | $490.9M | ||
| Q4 24 | $160.2M | $466.0M | ||
| Q3 24 | $157.9M | $519.1M | ||
| Q2 24 | $162.9M | $569.4M | ||
| Q1 24 | $166.5M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 5.09× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EPMRGNX
| Q4 25 | $5.4M | $-52.3M | ||
| Q3 25 | $7.8M | $-56.0M | ||
| Q2 25 | $10.5M | $-49.3M | ||
| Q1 25 | $7.3M | $33.6M | ||
| Q4 24 | $7.7M | $-31.6M | ||
| Q3 24 | $7.6M | $-40.5M | ||
| Q2 24 | $8.0M | $-45.5M | ||
| Q1 24 | $3.4M | $-55.5M |
自由现金流EPMRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率EPMRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度EPMRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率EPMRGNX
| Q4 25 | 5.09× | — | ||
| Q3 25 | 9.47× | — | ||
| Q2 25 | 3.06× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.69× | — | ||
| Q2 24 | 6.47× | — | ||
| Q1 24 | 11.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPM
| Crude Oil | $10.7M | 52% |
| Natural Gas Reserves | $7.4M | 36% |
| Natural Gas Liquids Reserves | $2.5M | 12% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
